Keywords
Coronary artery, oxidative stress, redox state, sGC activator, sGC stimulator, soluble guanylate cyclase

Correspondence
Masashi Tawa, Department of Pharmacology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan. Tel: +81-77-548-2182; Fax: +81-77-548-2183; E-mail: tawa@belle.shiga-med.ac.jp

Funding Information
This study was supported in part by the President’s Discretionary Fund from the Shiga University of Medical Science.

Received: 23 July 2016; Revised: 10 August 2016; Accepted: 10 August 2016

Pharma Res Per, 4(5), 2016, e00261, doi: 10.1002/prp2.261

do: 10.1002/prp2.261

Abstract
Coronary artery disease is associated with oxidative stress due to the excessive generation of free radicals in the vascular wall. This study investigated the impact of tert-butyl hydroperoxide (t-BuOOH), a peroxyl radical generator, on the redox state of soluble guanylate cyclase (sGC) in isolated monkey coronary arteries. Helically cut strips of endothelium-intact monkey coronary arteries treated with the nitric oxide synthase inhibitor N\textsuperscript{G}-nitro-L-arginine (10 \mu mol/L) were exposed for approximately 60 min to either no drug or t-BuOOH (100 \mu mol/L) in the presence and absence of \alpha-tocopherol (300 \mu mol/L). Relaxation and cGMP levels in response to the sGC stimulator BAY 41-2272 and the sGC activator BAY 60-2770 were assessed by organ chamber technique and enzyme immunoassay, respectively. The relaxant response to BAY 41-2272 was significantly impaired by the exposure to t-BuOOH, whereas the response to BAY 60-2770 was significantly augmented. In addition, vascular cGMP accumulation caused by BAY 41-2272 was decreased by the exposure to t-BuOOH, whereas for BAY 60-2770, it was increased. These effects of t-BuOOH were abolished by coincubation with \alpha-tocopherol. Furthermore, correlations were observed between BAY compound-induced relaxant magnitudes and cGMP levels. Therefore, it is concluded that increased oxidative stress leads to disruption of the sGC redox state in monkey coronary arteries. This finding is of great importance for understanding coronary physiology in primates.

Abbreviations
ANOVA, analysis of variance; CAD, coronary artery disease; E_{max}, maximal response; L-NA, \textsuperscript{G}-nitro-L-arginine; NO, nitric oxide; pD\textsubscript{2}, negative logarithm of the dilator concentration that caused half the E_{max}; PG, prostaglandin; sGC, soluble guanylate cyclase; t-BuOOH, tert-butyl hydroperoxide.

Introduction
Coronary artery disease (CAD), a major cause of death, is characterized by a reduction in coronary blood flow due to spasm, thrombus, embolus, and stenosis (Buja 2015). Excessive oxidative stress caused by free radicals in the primary lesion is an important feature of CAD. For example, the most reactive-free radical superoxide is increased in ischemic/reperfused canine coronary arteries (Mykytenko et al. 2007), in atherosclerotic coronary arteries from high cholesterol diet-fed monkeys (Supari et al. 1995), and in narrowed porcine coronary arteries after balloon injury (Nunes et al. 1997). An increase in superoxide production was also confirmed in the coronary arteries of patients with CAD (Azumi et al. 2002; Sorescu et al. 2002; Guzik et al. 2006). Moreover, the oxidative damage of cell membranes caused by free radicals is linked to human coronary atherogenesis (Mehrabi et al. 1999; van Dijk et al. 2012). The nitric oxide (NO)/soluble guanylate cyclase (sGC)/cGMP pathway has pivotal roles, such as vasodilation, antiaggregation, anti-inflammation, and antiproliferation,
in the coronary circulation system (Toda et al. 2011). Although NO stimulates cGMP synthesis by activating sGC, this cytosolic enzyme exists in either the NO-sensitive reduced form or the NO-insensitive oxidized/heme-free form. Briefly, if the ferrous (Fe²⁺) heme moiety is oxidized to the ferric (Fe³⁺) state or lost, NO loses its ability to activate sGC (Evgonov et al. 2006; Stasch et al. 2011). In recent years, it has been proposed that a shift of the sGC redox equilibrium toward the NO-insensitive state contributes to the onset and development of some cardiovascular diseases (Stasch et al. 2006; Chester et al. 2011). In contrast, sGC in coronary arteries may also be subjected to such redox regulation (Tawa et al. 2014a).

One determinant of vascular sGC redox equilibrium is the type of free radical and its derivatives. Superoxide, peroxynitrite, and hydrogen peroxide was suggested to be able to change sGC from the reduced form to the oxidized/heme-free form in isolated rat aortas (Stasch et al. 2006) and iliac arteries (Tawa et al. 2014b, 2015a) or in cultured sheep pulmonary artery smooth muscle cells (Zhou et al. 2008). However, there is no firm evidence that the sGC redox state in the coronary artery is also affected under oxidative stress conditions. Therefore, this study investigated this effect in isolated monkey coronary arteries by analyzing the influence of the peroxyl radical generator tert-butyl hydroperoxide (t-BuOOH). As now known, lipid peroxyl radicals are mediators of coronary atherogenesis.

Materials and Methods

Animal

Three male (14 to 15 years old) and three female (11 to 12 years old) crab-eating monkeys (Macaca irus) weighing 4 to 7 kg were used for this study. These monkeys had no cardiovascular or metabolic diseases. All procedures involving animals were approved by the Animal Care and Use Committee at Shiga University of Medical Science, and this study was performed based on guidelines in accordance with the recommendations of the Weatherall Report on “The Use of Non-Human Primates in Research”. The monkeys were housed individually in cages with various toys for environmental enrichment under controlled conditions of humidity (50 ± 5%), temperature (25 ± 2°C), and light (12 h light/12 h dark cycle), and their health and welfare were ensured by the researchers and the animal care staff with daily monitoring. A commercial primate pellet diet and fresh fruit/vegetables were given daily, and drinking water was available ad libitum. Routine anesthetic and/or analgesic agents were used appropriately, and every effort was made to minimize animal discomfort and pain.

Preparation

Each monkey under deep general anesthesia with ketamine (10 mg/kg, i.m.) and sodium pentobarbital (40 mg/kg, i.v.) was killed by bleeding, and the heart was rapidly excised. Coronary arteries (0.5 to 1.0 mm outside diameter) were isolated, the surrounding tissues cleaned, and the arteries were then cut helically into strips, with special care taken to preserve the endothelium. The functional integrity of the endothelium was verified by observing a relaxant response to acetylcholine (1 μmol/L). The strips were fixed vertically between hooks in a muscle bath (10 mL capacity) containing modified Ringer-Locke solution, which was aerated with a gas mixture 95% O₂ and 5% CO₂. The pH and temperature were maintained throughout the experiment at 7.4 and 37 ± 0.5°C, respectively. Constituents of the modified Ringer-Locke solution were as follows (mmol/L): NaCl 120, KCl 5.4, CaCl₂ 2.2, MgCl₂ 1.0, NaHCO₃ 25.0, and glucose 5.6. The hook anchoring the upper end of the strip was connected to the lever of an isometric force-displacement transducer (Nihon Kohden Kogyo Co., Tokyo, Japan). The resting tension of the strip was adjusted to 1.0 g, which is optimal for inducing maximum contraction. Before the start of experiments, all strips were allowed to equilibrate in the bathing medium for 60 to 90 min. During this time the solution was replaced every 10 to 15 min.

Mechanical responses

Isometric contractions and relaxations were displayed on an ink-writing oscillograph. Because the presence of endothelium-derived NO makes it difficult to assess the sGC redox state (Tawa et al. 2015b), the following experiments were performed in the presence of the NO synthase inhibitor N⁵-nitro-L-arginine (L-NA, 10 μmol/L). The preparations were exposed to no drug for 60 min (control) or to t-BuOOH (100 μmol/L) with and without α-tocopherol (300 μmol/L) in the bathing solution. These concentrations were determined based on previous studies (de Nigris et al. 2000; Stevanovic et al. 2009). The strips were then treated with prostaglandin (PG) F₂₅ in a concentration range 1 to 3 μmol/L to obtain an adequate preconstriction level, which was not significantly different between groups [developed tension, 0.46 ± 0.05 g (control), 0.47 ± 0.07 g (t-BuOOH), and 0.58 ± 0.06 g (+α-tocopherol)]. After the contraction reached a plateau, concentration–response curves for the reduced sGC stimulant BAY 41-2272 and the oxidized/heme-free sGC stimulant BAY 60-2770 were obtained by adding the drug directly to the bathing medium in cumulative concentrations. At the end of each experiment, 100 μmol/L papaverine was added to induce maximal relaxation,
which was taken as 100% for the relaxations induced by agonists.

**cGMP measurements**

The content of cGMP in monkey coronary artery strips was measured according to a method described previously (Tawa et al. 2014a). Briefly, the strips, which were pre-contracted with PGF$_{2\alpha}$ after exposure to each condition stated above, were treated with BAY 41-2272 (100 nmol/L) or BAY 60-2770 (1 nmol/L) for approximately 30 min and were then immediately plunged into liquid nitrogen. To evaluate the correlation between relaxation and cGMP accumulation, the vasorelaxant ability was calculated as a percentage of PGF$_{2\alpha}$-induced precontraction. The tissues were homogenized in 300 μL of 5% trichloroacetic acid at 0°C with a glass homogenizer. After centrifugation at 1500 g for 10 min, water-saturated ether was added to the collected supernatant, and the residual ether was removed from the aqueous layer by heating the sample at 70°C for 5 min. An aliquot of extract was then used for cGMP determination, using a commercially available enzyme immunoassay kit (Cayman Chemical Co., Ann Arbor, MI). The cGMP level in the tissue was normalized to the protein content measured in the same extract. Protein content was determined by the Bradford assay.

**Drugs**

The following drugs were used: t-BuOOH, α-tocopherol, and L-NA (Sigma Chemical Co, St. Louis, MO); BAY 41-2272 and BAY 60-2770 (kindly provided by Dr. Johannes-Peter Stasch of the Institute of Cardiovascular Research, Pharma Research Centre, Bayer AG, Wuppertal, Germany); PGF$_{2\alpha}$ (Pharmacia-Upjohn, Tokyo, Japan); ketamine (Sankyo, Tokyo, Japan); sodium pentobarbital and papaverine hydrochloride (Dainippon-Sumitomo Pharma Co., Osaka, Japan); Ethanol, dimethyl sulfoxide, and sodium bicarbonate buffer (pH 9.2) were used as a solvent for α-tocopherol, BAY compounds, and PGF$_{2\alpha}$, respectively. Distilled water was used to dissolve all other drugs and to prepare serial dilutions, as required, from stocks on the day of the experiment.

**Statistics**

All values are expressed as the mean ± SEM. Concentration–response curves were fitted by nonlinear regression analysis using the Graph Pad Prism 6.0 software (Graph Pad Software Inc., San Diego, CA), and the maximal response (E$_{\text{max}}$) and negative logarithm of the dilator concentration that caused half the E$_{\text{max}}$ (pD$_2$) were determined. Concentration–response curves were analyzed with two-way repeated measures analysis of variance (ANOVA) and Bonferroni post hoc test. E$_{\text{max}}$ and pD$_2$ values were compared using the Bonferroni multiple comparisons test after one-way ANOVA. Comparison of the cGMP levels was performed using one-way ANOVA followed by Bonferroni post test. Correlations were tested using the Pearson correlation test. Significant differences were considered significant at P < 0.05.

**Results**

**Influence of t-BuOOH on BAY compound-induced vasorelaxation**

The addition of either BAY 41-2272 at concentrations of 100 pmol/L to 10 μmol/L or BAY 60-2770 at 1 pmol/L to 100 nmol/L produced a concentration-dependent relaxation of endothelium-intact monkey coronary arteries treated with L-NA in all experimental groups. The efficacies of these drugs, as reflected by the E$_{\text{max}}$ values, were comparable between groups (Table 1). However, as shown in Figure 1A and B, t-BuOOH exposure resulted in a rightward displacement of the concentration–response curve for BAY 41-2272, whereas the BAY 60-2770 concentration–response curve was shifted to the left. In addition, t-BuOOH exposure somewhat decreased the pD$_2$ values for BAY 41-2272 but increased those for BAY 60-2770 (Table 1), which indicated a reduced and enhanced sensitivity of the arteries to the former and the latter, respectively. These effects of t-BuOOH were significantly inhibited in the presence of α-tocopherol (Fig. 1A and B; Table 1).

**Influence of t-BuOOH on BAY compound-induced cGMP accumulation**

As shown in Figure 2A, cGMP levels in endothelium-intact monkey coronary arteries stimulated with BAY

| Drug | Control | t-BuOOH | +α-tocopherol |
|------|---------|---------|---------------|
| BAY 41-2272 | pD$_2$ | 7.39 ± 0.28 | 6.89 ± 0.24 | 7.04 ± 0.27 |
| | E$_{\text{max}}$ (%) | 93.8 ± 1.5 | 89.0 ± 3.2 | 95.2 ± 1.8 |
| BAY 60-2770 | pD$_2$ | 9.61 ± 0.11 | 10.40 ± 0.25* | 9.46 ± 0.12 † |
| | E$_{\text{max}}$ (%) | 95.5 ± 1.0 | 96.4 ± 0.8 | 96.2 ± 1.5 |

Data are the mean ± SEM of six experiments.

*P < 0.05, compared to the control.
†P < 0.01, compared to t-BuOOH. Statistical analysis was performed using one-way ANOVA with Bonferroni post hoc test.
41-2272 (100 nmol/L) were decreased by t-BuOOH exposure, which was reversed by coincubation with α-tocopherol. In contrast, Figure 2B shows that BAY 60-2770 (1 nmol/L) induced greater cGMP accumulation in the presence of t-BuOOH than in its absence. This augmentation by t-BuOOH was not observed when α-tocopherol was present.

**Correlation between relaxation and cGMP accumulation**

In endothelium-intact monkey coronary arteries treated with L-NA, the degrees of remaining contraction (% pre-contraction) after BAY 41-2272 addition showed a negative relationship ($P = 0.0015$) with the tissue cGMP levels (Fig. 3A), which indicated an association between this compound-induced relaxation and cGMP synthesis. Similar to BAY 41-2272, there was also a good correlation...
directly linked to NO bioavailability and attention should be paid to its regulatory system. Therefore, the objective of this study was to evaluate the mechanism by which the redox state of coronary sGC is controlled under oxidative stress conditions. Additionally, responses to BAY 41-2272, a reduced sGC stimulant, and BAY 60-2770, an oxidized/heme-free sGC stimulant, were examined to achieve this goal. The BAY 41-2272-evoked relaxation of monkey coronary arteries was impaired under stress conditions caused by t-BuOOH, which was coupled with decreased cGMP generation. In contrast, BAY 60-2770 produced greater relaxation as well as higher levels of cGMP in coronary arteries exposed to t-BuOOH. Consistent with these results, Safaya et al. (2005) showed that exogenously applied lysophosphatidylcholine, a lipid peroxidation product, attenuates the relaxation of porcine coronary arteries induced by an NO donor through the induction of oxidative stress. Taken together, these findings suggest that the heme iron of sGC in the coronary artery undergoes oxidation under oxidative stress conditions, resulting in a shift of the redox balance toward the NO-insensitive state. This is the first evidence to show a relationship between oxidative stress and the sGC redox state in the coronary artery and is important for understanding coronary atherosclerosis. However, it is necessary to examine the sGC redox state in atherosclerotic coronary arteries in the future.

Figure 3. Relationship between relaxation and cGMP accumulation in response to BAY 41-2272 (A) or BAY 60-2770 (B). The relaxation ability was calculated as a percentage of precontraction induced by prostaglandin F2α (% precontraction). White, control; black, t-BuOOH; gray, +α-tocopherol. Statistical analysis was performed using Pearson correlation test.

(P = 0.0047) for BAY 60-2770 to cause relaxation and stimulate cGMP accumulation (Fig. 3B). These results suggest that the changes in relaxant responses to BAY compounds by exposure to t-BuOOH are attributable to an increase or decrease in cGMP production.

Discussion

The NO/sGC/cGMP pathway is often abnormal in the diseased coronary artery (Förstermann et al. 1988; Berkenboom et al. 1989; Schächinger and Zeiher 1995; Yamagishi et al. 1995). In this regard, the sGC redox equilibrium is

© 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
α-tocopherol, a natural form of vitamin E, was used as a tool for elucidating the mechanism of t-BuOOH-induced actions in this study. Briefly, the results obtained may not always indicate the utility of α-tocopherol as a therapeutic agent. Verlangieri and Bush (1992) histologically demonstrated the antiatherogenic effect of dietary α-tocopherol in monkeys, whereas Rainwater et al. (2007) reported that vitamin E supplementation induces smaller high-density lipoprotein size in baboons. In addition, the results of clinical trials using vitamin E for the treatment of CAD have been inconsistent (Kirmizis and Chatzidimitriou 2009). Because several studies assessing the usefulness of vitamin E are continuously in progress, the answer of whether α-tocopherol is of clinical benefit will be obtained in due course.

Several studies demonstrated that sex differences are present in coronary function (Cox and Cohen 1997; Barber et al. 1998; Wong et al. 2015). In this regard, although a small sample number and mismatched age are not suitable for making a conclusion, similar influences of t-BuOOH on vascular reactivity to BAY compound were observed in coronary arteries obtained from male (Fig. S1) and female (Fig. S2) monkeys. However, the effects in females were greater than in males. This may be because male coronary arteries, compared to female coronary arteries, are intrinsically under high oxidative stress conditions (Wong et al. 2015). Age mismatch may not be a cause of the sex difference in t-BuOOH-induced effects because our recent study showed that aging does not affect vascular sGC redox equilibrium (Shimosato et al. 2016). Anyway, it is likely that if excessive oxidative stress occurs in the coronary artery, the sGC redox equilibrium shifts to the NO-insensitive state regardless of sex.

There is currently no analytical method to quantitate the expression of individual forms of sGC at the tissue level. Therefore, according to a number of previous reports (Zhou et al. 2008; Costell et al. 2012; Tawa et al. 2014a,b, 2015a,b; Goulopoulou et al. 2015), two different NO-independent stimulants acting on sGC were used in this study as valuable tools for indirectly assessing the redox state of the enzyme. As described elsewhere (Evgenov et al. 2006; Stasz et al. 2011), NO acts synergistically with the sGC stimulator BAY 41-2272, but only additively with the sGC activator BAY 60-2770. Although this is the reason why this study was performed in the presence of L-NA, whether this condition is physiological is unclear. Of course, coronary endothelial function is impaired in patients with CAD (Gutierrez et al. 2013), yet it must be multifarious how much the endothelium-derived NO production is decreased. Because there is a report showing that NO reacts with and traps peroxyl radicals (O’Donnell et al. 1997), the outcomes might differ in the presence and absence of L-NA. Even so, the conclusion that oxidative stress interferes with the sGC redox equilibrium in the coronary artery does not change.

Another limitation of this study is that the influence of chronic exposure to t-BuOOH was not assessed. Oxidation of the sGC heme moiety from the ferrous to ferric state subsequently results in heme detachment from the enzyme, which facilitates degradation of the enzyme by the ubiquitin-proteasome system (Meurer et al. 2009). In fact, Neo et al. (2011) indicated an sGC depleting effect of the heme specific oxidant ODQ in organoid cultured bovine coronary arteries. Furthermore, the same group showed that prolonged exposure of coronary arteries to angiotensin II causes the downregulation of sGC accompanied by oxidative stress induction (Patel et al. 2016). Consequently, the efficacy of sGC activators as well as NO donors and sGC stimulators may be reduced under chronic oxidative stress conditions. This is a future research issue.

In conclusion, this study demonstrated that t-BuOOH-induced oxidative stress conditions lead to a shift of the sGC redox equilibrium toward the oxidized/heme-free form in monkey coronary arteries. This finding will provide a better understanding of the mechanism by which the NO/sGC/cGMP pathway is regulated in the diseased coronary artery in primates.

Acknowledgements

The authors thank Dr Johannes-Peter Stasch (Institute of Cardiovascular Research, Pharma Research Centre, Bayer AG) for the gift of BAY compounds. We also thank the staff of the Research Center for Animal Life Science, Shiga University of Medical Science for their kind and tireless assistance.

Author Contributions

Tawa and Okamura participated in research design, wrote or contributed to the writing of the manuscript. Tawa also conducted the experiments and performed data analysis.

Disclosures

None declared.

References

Ayala A, Muñoz MF, Argüelles S (2014). Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014: 360438.

Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, et al. (2002). Superoxide generation in directional coronary
atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 22: 1838–1844.
Barber DA, Burnett JC Jr, Fitzpatrick LA, Sieck GC, Miller VM (1998). Gender and relaxation to C-type natriuretic peptide in porcine coronary arteries. J Cardiovasc Pharmacol 32: 5–11.
Berkenboom G, Unger P, Fontaine J (1989). Atherosclerosis and responses of human isolated coronary arteries to endothelium-dependent and -independent vasodilators. J Cardiovasc Pharmacol 14(Suppl 11): S35–S39.
Buja LM (2015). Coronary artery disease: pathological anatomy and pathogenesis. Pp. 1–20 in J. T. Willerson and D. R. Holmes Jr, eds. Coronary artery disease. Springer, London.
Chester M, Seedorf G, Tourneux P, Gien J, Tseng N, Grover T, et al. (2011). Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 301: L753–L764.
Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, et al. (2012). Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol 3: 128.
Cox DA, Cohen ML (1997). Influence of gender on vasomotor effects of oxidized low-density lipoprotein in porcine coronary arteries. Am J Physiol 272: H2577–H2583.
van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A, et al. (2012). Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 53: 2773–2790.
Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP (2006). NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755–768.
Förstermann U, Mügge A, Alheid U, Haverich A, Frölich JC (1988). Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 62: 185–190.
Goldstein S, Samuni A (2005). Intra- and intermolecular oxidation of oxymyoglobin and oxyhemoglobin induced by hydroxyl and carbonate radicals. Free Radic Biol Med 39: 511–519.
Goulopoulos S, Hannan JL, Matsumoto T, Ogbi S, Ergul A, Webb RC (2015). Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes. Am J Physiol Heart Circ Physiol 309: H297–H304.
Gutiérrez E, Flammer AJ, Lerman LO, Elizaga J, Lerman A, Fernández-Avilés F (2013). Endothelial dysfunction over the course of coronary artery disease. Eur Heart J 34: 3175–3181.
Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybolski P, et al. (2006). Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 26: 333–339.
Kirmizis D, Chatzidimitriou D (2009). Antiatherogenic effects of vitamin E: the search for the Holy Grail. Vasc Health Risk Manag 5: 767–774.
Mehrabi MR, Ekmeckioğlu C, Tatzber F, Oguogho A, Ullrich R, Morgan A, et al. (1999). The isoprostane, 8-epi-PGF2 alpha, is accumulated in coronary arteries isolated from patients with coronary heart disease. Cardiovasc Res 43: 492–499.
Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, et al. (2009). Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 105: 33–41.
Mykytenko J, Kerendi F, Reeves JG, Kin H, Zatta AJ, Jiang R, et al. (2007). Long-term inhibition of myocardial infarction by postconditioning during reperfusion. Basic Res Cardiol 102: 90–100.
Nantes IL, Faljoni-Alário A, Nascimento OR, Bandy B, Gatti R, Bechara EJ (2000). Modifications in heme iron of free and vesicle bound cytochrome c by tert-butyl hydroperoxide: a magnetic circular dichroism and electron paramagnetic resonance investigation. Free Radic Biol Med 28: 786–796.
Neo BH, Kandhi S, Wolin MS (2011). Roles for redox mechanisms controlling protein kinase G in pulmonary and coronary artery responses to hypoxia. Am J Physiol Heart Circ Physiol 301: H2295–H2304.
de Nigris F, Youssef T, Ciafré S, Franconi F, Anania V, Condorelli G, et al. (2000). Evidence for oxidative activation of c-Myc-dependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits: protective effects of vitamin E. Circulation 102: 2111–2117.
Nunes GL, Robinson K, Kalynych A, King SB 3rd, Sgoutas DS, Berk BC (1997). Vitamins C and E inhibit O2- production in the pig coronary artery. Circulation 96: 3593–3601.
O’Donnell VB, Chumley PH, Hogg N, Bloodsworth A, Darley-Usmar VM, Freeman BA (1997). Nitric oxide inhibition of lipid peroxidation: kinetics of reaction with lipid peroxyl radicals and comparison with alpha-tocopherol. Biochemistry 36: 15216–15223.
Patel D, Alhawaj R, Kelly MR, Accarino JJ, Lakhkar A, Gupte SA, et al. (2016). Potential role of mitochondrial superoxide decreasing ferrochelatase and heme in coronary artery soluble guanylate cyclase depletion by angiotensin II. Am J Physiol Heart Circ Physiol 310: H1439–H1447.
Rainwater DL, Mahaney MC, Vandelberg JL, Wang XL (2007). Vitamin E dietary supplementation significantly affects...
multiple risk factors for cardiovascular disease in baboons. Am J Clin Nutr 86: 597–603.

Safaya R, Chai H, Kouguias P, Lin P, Lumsden A, Yao Q, et al. (2005). Effect of lysophosphatidylcholine on vasoconstrictor functions of porcine coronary arteries. J Surg Res 126: 182–188.

Schächinger V, Zeiher AM (1995). Quantitative assessment of coronary vasoreactivity in humans in vivo: Importance of baseline vasomotor tone in atherosclerosis. Circulation 92: 2087–2094.

Shimosato T, Tawa M, Iwasaki H, Imamura T, Okamura T (2016). Aging does not affect soluble guanylate cyclase redox state in mouse aortas. Physiol Rep 4: e12816.

Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, et al. (2006). Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552–2561.

Stasch JP, Pacher P, Evgenov OV (2011). Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123: 2263–2273.

Stevanovic D, Zhang D, Blumenstein A, Djuric D, Heine H (2009). Effects of hydroperoxides on contractile reactivity and free radical production of porcine brain arteries. Gen Physiol Biophys 28 (Special Issue): 93–97.

Stocker R, Keaney JF Jr (2004). Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381–1478.

Supari F, Ungerer T, Harrison DG, Williams JK (1995). Fish oil treatment decreases superoxide anions in the myocardium and coronary arteries of atherosclerotic monkeys. Circulation 91: 1123–1128.

Tawa M, Geddawy A, Shimosato T, Iwasaki H, Imamura T, Okamura T (2014a). Soluble guanylate cyclase redox state under hypoxia or hypoxia/reoxygenation in isolated monkey coronary arteries. J Pharmacol Sci 125: 169–175.

Tawa M, Shimosato T, Iwasaki H, Imamura T, Okamura T (2014b). Effects of peroxynitrite on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries. J Vasc Res 51: 439–446.

Tawa M, Shimosato T, Iwasaki H, Imamura T, Okamura T (2015a). Different influences of extracellular and intracellular superoxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries. J Cardiovasc Pharmacol 65: 160–167.

Tawa M, Shimosato T, Iwasaki H, Imamura T, Okamura T (2015b). Effects of hydrogen peroxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries. Free Radic Res 49: 1479–1487.

Toda N, Tanabe S, Nakanishi S (2011). Nitric oxide-mediated coronary flow regulation in patients with coronary artery disease: recent advances. Int J Angiol 20: 121–134.

Verlangieri AJ, Bush MJ (1992). Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. J Am Coll Nutr 11: 131–138.

Wong PS, Roberts RE, Randall MD (2015). Sex differences in the role of NADPH oxidases in endothelium-dependent vasorelaxation in porcine isolated coronary arteries. Vascul Pharmacol 72: 83–92.

Yamagishi M, Nissen SE, Booth DC, Gurley JC, Koyama J, Kawano S, et al. (1995). Coronary reactivity to nitroglycerin: intravascular ultrasound evidence for the importance of plaque distribution. J Am Coll Cardiol 25: 224–230.

Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eckels M, Spyroulias G, et al. (2008). Soluble guanyl cyclase activation by HMR-1766 (atigau) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 295: H1763–H1771.

Additional Supporting Information may be found online in the supporting information tab for this article:

Figure S1. Effects of t-BuOOH on BAY 41-2272 (A)- and BAY 60-2770 (B)-induced relaxation of endothelium-intact male monkey coronary arteries treated with N^3-nitro-L-arginine in the absence or presence of a-tocopherol (Toco). Each point and bar represents the mean ± SEM of three experiments. *P < 0.05, compared to the control; ††P < 0.01, compared to t-BuOOH. Statistical analysis was performed using two-way repeated measures ANOVA with Bonferroni post hoc test.

Figure S2. Effects of t-BuOOH on BAY 41-2272 (A)- and BAY 60-2770 (B)-induced relaxation of endothelium-intact female monkey coronary arteries treated with N^2-nitro-L-arginine in the absence or presence of a-tocopherol. The relaxation is presented as a value relative to that induced by papaverine. White, control; black, t-BuOOH; gray, a-tocopherol (Toco). Each point and bar represents the mean ± SEM of three experiments. *P < 0.05 and **P < 0.01, compared to the control; ††P < 0.01, compared to t-BuOOH. Statistical analysis was performed using two-way repeated measures ANOVA with Bonferroni post hoc test.